All In Biotech

Drug Trial Radar · NCT04968613

Dopaminergic Mechanism of Memory Impairment in Parkinson's Disease

Dopaminergic Mechanism of Temporal Working Memory Impairment in Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 1, 2018

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Peking University Third HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chinese Academy of Sciences
First posted
Jul 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The cognitive impairment of Parkinson's disease is non amnestic, which is characterized by working memory impairment and executive dysfunction. The current drug therapy (such as levodopa, dopamine receptor agonists) and surgical treatment (such as deep brain electrical stimulation, thalamic lesion) not only can not effectively alleviate cognitive impairment, but also may aggravate cognitive and speech behavior abnormalities. This project will explore how dopamine regulates temporal working memory in human research by combining drug intervention, neuroimaging and cognitive tasks.

Conditions

  • Parkinson Disease
  • Memory Impairment

Interventions

  • Madopar monotherapyDrug

    In addition to basic treatment, the patient also received Madopar treatment

  • senfrol monotherapyDrug

    In addition to the basic treatment, the patient also received the rofosson treatment

  • placebo monotherapyDrug

    In addition to basic treatment, the patient also received selegiline treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of cognition functionTime frame: 12 months after the trail

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.